Friday, March 24, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Researchers Achieve Breakthrough in Prion Disease Treatment

by Global Biodefense Staff
June 27, 2012

Researchers from Linköping University in Sweden, in cooperation with colleagues from the University Hospital of Zurich in Switzerland, have developed self-illuminating polymers with the ability to home in on toxic prions and render them harmless.

These luminescent conjugated polymers (LCPs) represent a novel class of antiprion agents offer the potential to cure fatal nerve-destroying illnesses.

Prion disease is a group of progressive conditions that affect the brain and nervous system of humans and animals. Human prion diseases include sporadic Creutzfeldt-Jakob disease (CJD), Kuru, variant Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker Syndrome.  Prion illnesses can be inherited, occur spontaneously or through infection, such as from ingesting meat infected with Bovine Spongiform Encephalopathy, or Mad Cow Disease.

The researchers say this is the first time anyone has been able to demonstrate the possibility of treating these types of illnesses with LCP molecules. In a study recently published in the Journal of Biological Chemistry, the team tested the LCPs on tissue sections infected with prions. The results indicate that the number of prions, as well as their toxicity and infectibility, decreased drastically.

Scientists are hopeful that the effects on prion infections seen with this research will translate to work on other nervous-system diseases, such as Alzheimer’s. They plan to expand their studies towards such efforts and look at further customizing the molecules.

This Swedish-Swiss study was supported in part by the Luminescent Polymers for In vivo Imaging of Amyloid Signatures (LUPAS) project, Swedish Foundation for Strategic Research, Novartis Research Foundation, and the EU’s Seventh Framework Programme (FP7).

Tags: Prions

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC